Syndax Pharmaceuticals(DE:1T3)
€8.55+0.01 (+0.07%)
DE:1T3
Syndax Pharmaceuticals stock drug pipeline
€8.55
At close:+0.01 (+0.07%)
Syndax Pharmaceuticals (1T3) Drug Pipeline
4 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Syndax Pharmaceuticals Inc. (DE:1T3) have in its pipeline
Syndax Pharmaceuticals DE:1T3 is currently developing the following drugs: Revumenib, Sndx-5613, Revumenib, Intensive Chemotherapy Regimen, Sndx-5613, Chemotherapy Regimen, Hidac, Axatilimab, Chemotherapy, Revumenib, Revumenib, Revumenib, Cobicistat, Atezolizumab, Entinostat, Pembrolizumab, Entinostat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

